LEGN Similar Chart Price Prediction
The price of LEGN is predicted to go up 3.04%, based on the high correlation periods with PCRX. The similarity of these two price pattern on the periods is 94.85%.
LEGN
PCRX
Up: 3.04%Similarity: 94.85%
LEGN Revenue Forecast
LEGN EPS Forecast
LEGN FAQs
What is bull’s view on LEGN?
What is bear's view on LEGN?
What is LEGN revenue forecast for next quarter？
What is LEGN eps forecast for next quarter？
LEGN Analyst's Forecast
Qize Ding
Redburn Atlantic
Strong Buy
2024-10-08
Price Target
$86
Upside
+78.94%
Redburn Atlantic analyst Qize Ding initiated coverage of Legend Biotech with a Buy rating and $86 price target. Legend is a commercial-stage biotechnology company with one marketed product, Carvykti, for the treatment of multiple myeloma, the analyst tells investors in a research note. The firm says that with "best-in-class" clinical data among approved BCMA CAR-T cell therapies, Legend's Carvykti has been granted recent approvals for the treatment of earlier-line indications.
